Perry Clutch 20

8 x 4.25 x 2 in.

20.3 x 11.3 x 5 cm.

(http://education.QuestDiagnostics.com/faq/FAQ164)
CHOL/HDLC RATIO 1.9 <5.0 (calc) EN
NON HDL CHOLESTEROL 85 <130 mg/dL (calc) EN
For patients with diabetes plus 1 major ASCVD risk
factor, treating to a non-HDL-C goal of <100 mg/dL
(LDL-C of <70 mg/dL) is considered a therapeutic
option.
HS CRP 0.2 mg/L EN
Reference Range
Optimal <1.0
Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.
For ages >17 Years:
hs-CRP mg/L Risk According to AHA/CDC Guidelines
<1.0 Lower relative cardiovascular risk.
1.0-3.0 Average relative cardiovascular risk.
3.1-10.0 Higher relative cardiovascular risk.
Consider retesting in 1 to 2 weeks to
exclude a benign transient elevation
in the baseline CRP value secondary
to infection or inflammation.
>10.0 Persistent elevation, upon retesting,
may be associated with infection and
inflammation.
Pearson TA, Mensah GA, Alexander RW, et al. Markers
of inflammation and cardiovascular disease:
application to clinical and public health practice:
A statement for healthcare professionals from the
Centers for Disease Control and Prevention and the
American Heart Association. Circulation 2003; 107(3):
499-511.
HOMOCYSTEINE 6.4 < or = 11.0 umol/L EN
Homocysteine is increased by functional deficiency of
folate or vitamin B12. Testing for methylmalonic acid
differentiates between these deficiencies. Other causes
of increased homocysteine include renal failure, folate
antagonists such as methotrexate and phenytoin, and
exposure to nitrous oxide.
Selhub J, et al., Ann Intern Med. 1999;131(5):331-9.
APOLIPOPROTEIN B 66 mg/dL EN
Reference Range <90
Risk Category:
Optimal <90
Moderate 90-129
High > or = 130

A desirable treatment target may be
<80 mg/dL or lower depending on the
risk category of the patient including
patients on lipid lowering therapies,
patients with ASCVD, diabetes with >1
risk factors, Stage 3 or greater CKD
with albuminuria, or heterozygous
PAGE